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Abstract 
Background: Cardiometabolic diseases like type 2 diabetes, metabolic syndrome, heart failure, and other 
cardiovascular complications are the leading cause of mortality and morbidity across the globe. These conditions 
are directly attributed to modifiable behaviors such as sedentary activity, poor diet, excessive consumption of 
alcohol, or smoking. Efforts aimed towards their prevention and management are, therefore, not only essential in 
the accomplishment of the healthy populations but also for eliminating the associated cost and health burdens. 
Dietary change is an important approach to the promotion of cardiometabolic health. Omega 3 (C20–22 ω 3) 
polyunsaturated fatty acids have pleiotropic effects on the functioning of cells, control inflammatory factors, and 
cellular events in vascular endothelial cells and cardiomyocytes. The hypolipemic, anti-arrhythmic, and anti-
inflammatory properties of fatty acids offer cardioprotection. Government agencies and national heart 
associations recommend increased consumption of omega 3 polyunsaturated fatty acids (PUFA) supplements and 
fish to prevent cardiometabolic diseases.  
Purpose of the Study: The purpose of this study is to investigate the role played by ω-3 and ω-6 
polyunsaturated fatty acids in promoting cardiometabolic health.  
Methods: The research study searched databases such as MEDLINE®, Embase, PsycINFO, CINAHL® and the 
Cochrane Library for relevant research studies evaluating the function/benefits of polyunsaturated fatty acids 
particularly ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic functions published between 
2011 and 2020. A total of 77 research studies were identified and used in the meta-analysis. 
Results: Results from the meta-analysis indicated that polyunsaturated fatty acids lower the risk for 
cardiovascular disease by limiting inflammation of blood vessels, reducing thrombosis, increasing levels of high-
density lipoproteins, reducing levels of low-density lipoproteins, and reducing risk factors associated with 
hypertension. 
Conclusion: Given the benefits of polyunsaturated fatty acids lower the risk for cardiovascular diseases indicted 
in the meta-analysis. Therefore, human diets must contain the required amounts of PUFA due to the associated 
benefits. 
 Manuscript no: JHCR-1-83 Volume: 1      Issue: 2      84 
J Health Care and Research 
 
 Review Article 
Citation: Halim M, Halim A. Omega 3 versus Omega 6 Polyunsaturated Fatty Acids in Cardio-Metabolic Health. J Health 
Care and Research. 2020 Jun 27;1(2):83-100. 
 
Background 
    Cardiometabolic Syndrome is a combination of 
metabolic dysfunctions characterized by impaired 
glucose tolerance, insulin resistance, hypertension, 
dyslipidemia, and central adiposity [1]. 
Cardiometabolic health encompasses metabolic and 
cardiovascular diseases [2]. Examples of 
cardiovascular diseases include heart failure, heart 
attack, and cardiomyopathy, among others, while 
metabolic complications include type 2 diabetes and 
metabolic syndrome [3]. According to [4], 
cardiometabolic diseases pose significant health and 
economic burden to the world with high prevalence 
rates expected. Other factors that predispose 
individuals to cardiometabolic diseases include a poor 
diet, sedentary lifestyle, short sleep duration, and 
prolonged sitting that are significant elements of the 
modern lifestyles [5]. Cardiometabolic diseases share 
risk factors, as evident in the impact of 
obesity/overweight and elevated blood pressure that 
can be modified through lifestyle choices and proper 
diet [6]. PUFAs are fatty acids containing more than 
one double bond in their chain with examples 
including omega-3 (ω-3), omega-6 (ω-6), and omega-9 
(ω-9) fats [7]. PUFAs can be easily obtained from 
various food products to enhance cardiometabolic 
health. This article reports the impact of omega-3 and 
omega-6 PUFAs in the promotion of cardiometabolic 
health. 
 
Methods 
Database Searches: 
    The research study employed systematic meta-
analysis to analyze different research studies. 
Concerning this, a systematic computerized literature 
search of EMBASE, PubMed, PsycINFO, MEDLINE as 
well as CINAHL databases was performed for different 
research studies published in English up to February 
2020. Generally, the search was conducted by 
combining a number of keywords as well as medical 
subheadings; furthermore, no limitations with regard 
to the search strategy were inserted. Some of the 
keywords used in the searches included: Omega-3, 
Omega-6, Polyunsaturated fatty acids, cardiometabolic 
health. On the other hand, some of the medical 
subheadings included cardiometabolic health benefits 
of Omega-3 and Omega-6, respectively. References 
from all the relevant literature were carefully hand 
searched from these databases and also used to 
identify additional relevant research studies. Following 
the initial search, a total of 151 relevant articles were 
located. 
 
Article Screening Methods: 
    Literature search yields hundreds to thousands of 
candidate documents where most of them get excluded 
after screening because they are not relevant to the 
topic under study. Screening candidate articles in a 
systematic review for inclusion takes much time when 
conducted manually [8]. Automated tools dedicated to 
screening candidate studies were employed to reduce 
human effort and to arrive at the main objective within 
a shorter period. The methods used are based on 
supervised machine learning techniques. Based on 
trained models, they were able to identify relevant 
keywords in the abstract of candidate articles. 
Keywords used here included omega 3, omega 6, 
cardiometabolic diseases, polyunsaturated fatty acids, 
and PUFA. Articles screened were elected from those 
which were published between 2010 and 2020 to help 
obtain the latest and most relevant information. The 
screening exercise yielded to 114 articles that were 
relevant to this topic and had the latest information 
about the contribution of omega 3 and 6 to 
cardiometabolic diseases. The screening method 
excluded those studies which did not meet a 
predefined set of characteristics. The results obtained 
were compared to the actual reviews inclusion list. The 
screening threshold rule used identified studies that 
mentioned Polyunsaturated fatty acids (PUFAs) and 
Cardiometabolic health in the study abstract. This rule 
excluded 91.6% of studies retrieved. 
 
Inclusion and Exclusion Criteria: 
    An exclusion/inclusion criterion used ensured that 
the selection of studies was unbiased and that the 
article selected focused on the main research question. 
An exclusion/ inclusion criterion was employed to first 
screen abstracts and tittles related to cardiometabolic 
diseases, omega 3, and omega 6 polyunsaturated fatty 
acids. The next full text was retrieved from these 
articles and screened to determine whether the content 
fits the eligibility criteria of this task. Covidence, which 
is an online systemic review management tool, was
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employed to offer independent abstract/ title 
screening, data extraction, full-text screening, and risk 
of bias assessment.  To selected quality sources, the 
criteria, thus, for the inclusion of research articles 
were as follows: the research study had to evaluate the 
function/benefits of polyunsaturated fatty acids, 
particularly ω-3 and ω-6 polyunsaturated fatty acids in 
promoting cardiometabolic functions. The second 
criteria are that the research had to be published 
between 2010 and 2020 to ensure relevancy. The third 
criterion that the research studies had to focus on 
human beings as opposed to animal studies. However, 
there were no limitations on the type of research paper 
included in the research study. After exclusion, a total 
of 20 high-quality research studies were acquired to be 
used in the research study, while 56 low-quality 
research studies were excluded. 
 
Results 
    Crowe-White et al. (2018) reported that different 
fatty acids have varying effects on cardiometabolic 
health [9]. For instance, the ratios of ω-3 to ω-6 is not 
only essential in the production of eicosanoid 
metabolites that influence the inflammatory and 
homeostatic responses but also critical in the 
pathogenesis of diseases like diabetes [10,11]. The 
imbalances  between  the  intake of ω-3  and  ω-6 may  
 
lead to the imbalances in gene-nutrient interactions 
and endogenous mediators that may lead to biological 
consequences that influence the disease risk [12,13]. 
Other studies by [14,15] emphasized the need for 
replacing saturated fats with unsaturated fats as part 
of dietary controls towards the management of 
cardiovascular diseases. Similarly, [9] asserted that the 
intake of ω-3 and ω-6 PUFAs is beneficial for lowering 
the risks for cardiometabolic conditions while [16] 
emphasized the important role played by the two fatty 
acids in the regulation of the platelet function and 
thrombosis.  
 
    The effect of using omega-3 and omega-6 has been 
illustrated in various studies. Mozaffarian (2009) 
examined the combined effect of various omega-3 fats 
such as EPA and DHA on multiple cardiovascular 
outcomes has also been revealed [15]. The results 
indicate the combined dose of EPA and DHA has an 
anti-arrhythmic effect for weeks, triglycerides 
lowering for months to a year, heart rate lowering 
effects for months, and antithrombotic activity for 
weeks as revealed in (Fig-1). Similarly, [17] reported 
that the average dose of 500mg of either EPA or DHA 
significantly reduce adverse cardiovascular outcomes, 
as revealed in (Fig-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      
Fig-1:  
    EPA and DHA relative strength in managing multiple cardiovascular outcomes [15]. Increased consumption of PUFA has the 
highest effect in reducing anti-arrhythmic followed by reducing triglycerides, lowering the blood pressure and antithrombosis. 
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Impact of ω-3 and ω-6 PUFAs in Inflammation 
and Cardiometabolic Health: 
    Inflammation is vital for people’s survival by 
providing protection against infection and injury [18]. 
However, excessive inflammation is a driver to some 
diseases like heart diseases, metabolic syndrome, 
arthritis, cancers, and Alzheimer’s [19]. The 
establishment of the link between inflammation and 
cardiometabolic diseases, therefore, requires the 
development of the pharmacological and therapeutic 
strategies that are intended at the reduction of the 
inflammatory processes [20]. Diet contributes to 
inflammation due to the impact of the various 
proinflammatory substances like the cytokines that 
influence the mechanisms contributing to the 
cardiometabolic diseases [21]. For instance, the 
atherogenesis mechanism that influences the 
development of acute cardiovascular events arises 
from inflammatory processes [22]. Omega-3 and 
omega-6 PUFAs are critical elements of diet intake that 
significantly influence the occurrence of inflammation 
in the body and hence influence the status of 
cardiometabolic health of the individuals [23,24]. 
 
    Despite the similarities in the benefits of ω-3 and ω-
6 PUFAs in cardiometabolic health, the two fatty acids 
are associated with certain differences [25]. For 
instance, while ω-3 fatty acids are known for their 
anti-inflammatory properties, a high intake of ω-6 
PUFAs is associated with inflammation [26]. The 
intake of ω-3 fatty acids also reduces the production of 
molecules such as eicosanoids and cytokines that are 
linked to inflammation [27]. Esser et al. (2015) report 
that chronic inflammation is linked to cardiometabolic 
diseases and hence implying that increased intake of 
ω-6 PUFAs may lead contribute to a high risk of 
conditions like obesity, cardiovascular disease, 
metabolic syndrome, and type 2 diabetes [28]. 
However, the work of [29] dismisses the theory that 
ω-6 PUFAs do not contribute to the inflammation. On 
the same note, [30] asserts that there is conflicting 
evidence regarding whether ω-6 PUFAs are 
proinflammatory or inflammatory. The work of [25] 
further states that the consumption of more ω-3 fatty 
acids is associated with a decreased risk of metabolic 
syndrome as compared to the consumption of ω-6. 
High consumption of seed oils contains levels of 
linoleic acid, which have been indicated to reduce 
oxidative stress, inflammation, and endothelial 
dysfunction [31]. 
 
    Dietary levels of linoleic acid have been implicated 
in increasing levels of cyclooxygenase 2, resulting in 
the production of proinflammatory cytokines from 
arachidonic acid [26]. This explains an increase in 
linoleic acid lowers levels of arachidonic acid by 
breaking down proinflammatory cytokines (Fig-3). An 
additional arachidonic independent pathway promotes  
       
Fig-2: 
    EPA and DHA that reduce cardiovascular outcomes. The redline represent the average dose of 500mg of either EPA or DHA 
which is linked with positive outcomes. Adapted from [17]. 
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or increases the production of oxidized linoleic acid 
metabolites as well as proinflammatory eicosanoids, 
which serve to activate NF-kB while at the same time 
increasing proinflammatory cytokines as well as 
chemokines  [26,32].   In   addition, the  provision   of  
linoleic acid among individuals at risk of being 
diagnosed with cardiovascular diseases reduced total 
cholesterol, triglycerides, body mass index, and systolic 
blood pressure after a 12 month follow up period, as 
seen in (Table-1). 
 
    Dietary levels of linoleic acid have been implicated in 
increasing levels of cyclooxygenase 2, resulting in     
the  production of   proinflammatory   cytokines  from  
 
arachidonic acid [26]. This explains which an increase 
in linoleic acid lowers levels of arachidonic acid by 
breaking down proinflammatory cytokines. An 
additional arachidonic independent pathway promotes 
or increases the production of oxidized linoleic acid 
metabolites as well as proinflammatory eicosanoids, 
which serve to activate NF-kB while at the same time 
increasing proinflammatory cytokines as well as 
chemokines [26,32]. In addition, the provision of 
linoleic acid among individuals at risk of being 
diagnosed with cardiovascular diseases reduced total 
cholesterol, triglycerides, body mass index, and systolic 
blood pressure after a 12 month follow up period, as 
seen in (Table-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
              
Fig-3: 
    The relative risk of coronary heart disease on the addition of linoleic acid. Increased consumption of linoleic acid reduces 
coronary heart disease outcomes [33]. 
 
Table-1: Clinical data on changes in cardiovascular outcomes after the provision of linoleic acid 
following a 12 month follow up. A reduction in the levels of total cholesterol and triglycerides is 
observed above [34] 
  Baseline 12 months follow up  
Statistical 
Significance  
  Control  Intervention Control  Intervention  p-value 
Total cholesterol  282 281.3 266.5 243.9 <0.0001 
Triglycerides  185.9 189 151.8 136.5 0.06 
Body mass index 25.4 25.1 24.5 24.3 0.26 
Systolic blood pressure  136.9 136.6 136.5 136.4 0.49 
Diastolic blood 
pressure  
88.5 88.5 87.9 87.5 0.38 
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    A key mechanism that results in the down-
regulation of the synthesis of proinflammatory 
cytokines such as interleukin 6, tumor necrosis factor-
alpha and monocyte chemoattractant protein-1 occurs 
in the adipose tissue [34,35]. DHA and EPA bind to G-
protein coupled receptors present in the adipocytes 
and macrophages, resulting in the activation as well as 
the internalization of β-arrestin-2, and the formation 
of a complex GPR120/β-arrestine-2 [27]. The complex 
dissociates to transforming growth factor-beta (TGF-β) 
activated kinase 1 binding protein 1 (TAB1), which has 
been implicated in inhibiting and downregulating the 
activity of nuclear factor kappa B (NF-ĸB) [36,37]. 
Incorporating DHA into the lipid membrane also 
disrupts the activity of toll-like receptor 4 and inhibits 
several essential pathways related to fatty acid 
synthesis [27,34,38]. In addition, the presence of DHA 
and EPA downregulates the activity of nicotinamide 
adenine dinucleotide phosphate oxidase, which is key 
to producing reactive oxygen species required in the 
signaling of TLR-4 [38]. The mechanism linking 
PUFAs to inflammation is revealed below in (Fig-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of ω-3 and ω-6 PUFAs in Hypertension: 
    Recent studies reveal that maintaining low blood 
pressure even among individuals not diagnosed with 
hypertension is essential in reducing the incidences of 
cardiovascular diseases [39]. PUFAs regulate blood 
pressure through a number of different mechanisms, 
with the most common one is promoting the release of 
renin from the kidney [40]. Diets rich in omega-3 fatty 
acids have also been shown to suppress the activity of 
ACE (angiotensin converting enzyme) while at the 
same time suppressing the formation of angiotensin II 
which significantly improves the production of 
endothelial nitric oxide, a potent vasodilator while at 
the same time suppressing the action of Transforming 
Growth Factor-Beta [41,42]. The process by which 
PUFAs reduce the incidence of hypertension is revealed 
below in (Fig-5). 
         
Fig-4: 
    Roles of PUFA in inhibiting the activities of proinflammatory cytokines. The first step shows the binding of DHA and EPA, 
resulting in the activation and binding of Beta-arrestin-2, which breaks down to produce TABI, which inhibits TAKI and 
disrupting the remaining pathways [39]. 
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    A meta-analysis carried out by [43] also assessed 
the efficacy of omega-3 supplementation on pre-
eclampsia or hypertension. The meta-analysis revealed  
 
 
which compiled 14 different results indicated that the 
use of omega-3 fats had a protective effect on pre-
eclampsia as indicated by the meta-analysis summary 
below (Fig-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
Fig-5: 
    The role of polyunsaturated fatty acids and their role in managing hypertension. PUFAs. Step 1 shows how arachidonic acid 
increases vasodilation. The second pathway shows inhibition of ACE on the blood pressure level. The third pathway shows the 
action of P450 isoforms in nitric oxide production [39]. 
 
Fig-6: 
    Meta-analysis results showing the effectiveness of omega-3 supplementation in reducing hypertension. 
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    PUFAs have been shown to induce the formation of 
nitric oxide, which prevents vasoconstriction [44]. A 
6:1 ratio mixture of EPA: DHA was provided to Wister 
rats. Examined whether chronic intake of induces the 
function of angiotensin II in rats [45]. The results 
revealed that the consumption of chronic EPA: DHA 
ratios prevented Ang-II induced hypertension as well 
as endothelial dysfunction by limiting the activity of 
COX-derived oxidative and NADPH oxidase stress. The 
results have been indicated in (Fig-7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    EPA and DHA reduce hypertension by altering 
various hemodynamic. For instance, the use of o0f EPA 
and DHA has various effects on blood pressure, heart 
rates, cardiac diastolic filling, and arterial compliance, 
as summarised in the information provided in    
(Table-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of ω-3 and ω-6 PUFAs in Thrombogenesis: 
    Polyunsaturated fatty acids have been shown to 
exhibit antithrombotic properties [47]. Available 
studies indicate that the Eskimo diet that is rich in 
intake of seafood contains high levels polyunsaturated 
fatty acids which have been directly linked with low 
incidences of cardiovascular diseases as well as a 
decrease in thrombogenesis [48,49]. Most of the above 
effects have been described in populations found in 
different areas although the inverse relationship 
between intake of omega-3 polyunsaturated fatty acids 
has been associated with platelet aggregation, 
fibrinolysis, and coagulation has not been completely 
elucidated [50]. Nonetheless, in-vitro and in vivo 
studies reveal that the use of polyunsaturated fatty 
acids supplementation reduces the synthesis of 
thromboxane 2, platelet adhesion and activation and 
decreases the concentration and activity of 
plasminogen activator inhibitor-1 [16,51]. The specific 
mechanism in which omega-3 polyunsaturated fatty 
acids decrease levels of thrombogenesis has been 
studied, especially in platelets. 
 
    High levels of common polyunsaturated fatty acids, 
such as EPA and DHA, favor the replacement of 
arachidonic acid within the phospholipids of the cell 
membrane [52]. This decreases the binding of 
arachidonic acid on cyclooxygenase 1, reducing the 
synthesis of thromboxane A2, which is considered as 
an element that increases platelet aggregation and 
vasoconstriction [52,53]. The approach also produces 
Thromboxane A3, which exerts a low biological effect 
compared to thromboxane A2. Another suggested 
mechanism in which omega-3 polyunsaturated fatty 
acids reduces thrombogenesis involves the synthesis of 
protectin DX which is considered a product of 
dihydroxylation of DHA [54,55]. The product inhibits 
the activity of cyclooxygenase 1 and cyclooxygenase 2 
in neutrophils and platelets, reducing platelet 
aggregation and activation, as indicated in (Fig-8).  
 
    DHA and EPA were reported to have minimal effects 
on thrombosis or coagulation. Furthermore, the use of 
DHA and EPA are indicated to reduce inflammation 
and oxidative stress, which have been linked with 
thrombogenesis. The results are indicated in      
(Table-3). 
 
 
Fig-7: 
    Chronic intake of PUFAs prevents Angiotensin-II 
hypertension in rats in the first week when fed orally before 
the level rises when rats are fed using a somatic pump. The 
results adapted from [45]. 
Table-2: Effect of EPA and DHA on blood 
pressure variables [46] 
  EPA  DHA 
Cardiac 
hemodynamics 
Has minimal effects 
on blood pressure  
Reduces blood 
pressure level  
Reduces heart rate  
Reduces heart 
rate 
Promotes cardiac 
diastolic filling  
Promotes 
cardiac diastolic 
filling  
Promotes arterial 
compliance  
Promotes 
arterial 
compliance  
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    Human beings associated thromboembolism with 
endothelial function [56]. Previous studies have 
already reported on the improved effect of EPA and 
DHA on the endothelial function of arteries, but the 
impact on veins is largely unclear [57,58]. [60] report 
that administration of EPA: DHA in a ration of 6:1 for a 
week resulted in the release of acetylcholine, which 
causes relaxation of veins at low concentrations. Also 
EPA: DHA ratios of 1:1 increased acetylcholine levels 
resulting in the relaxation of femoral vein. Corn oil did 
not show any difference (Fig-9).  
 
Impact of ω-3 and ω-6 on Lipid Profiles: 
    Maintaining and monitoring healthy levels of lipids 
circulating within the bloodstream remains one of the 
essential methods used to diagnose different 
cardiovascular diseases [47]. A lipid panel or profile is 
considered as a group of individual  tests that  evaluate 
an individual risk of developing different 
cardiovascular treatments [60]. Normally, lipid 
profiles consist of various types of molecules, including 
total cholesterol, low-density lipoprotein, high-density 
lipoprotein, and triglycerides [61]. HDL is regarded as 
the good cholesterol and removes excess cholesterol 
from arteries and also carries low-density lipoproteins 
cholesterol back to the liver for decomposition and 
removal from the body [62,63]. The application of 
diets rich in either omega-6 or omega 3 fats 
significantly improves cardiovascular health by directly 
improving the activity of HDL and lowering levels of 
LDLs. [64] observed that a diet rich in omega-3 
supplementation greatly improved lipid metabolism, 
reduced triglycerides levels, and increased activity of 
HDLs as well as anti-platelet activity and anti-
inflammatory effects. Similarly, a systematic review 
and meta-analysis by [1] observed that consumption   
of polyunsaturated  fatty acids  was  associated  with  a  
      
Fig-8: 
    Role of polyunsaturated fatty acids in thrombogenesis. The first mechanism involves reducing the synthesis of thromboxane 
A2 and the effect of protectin DX [39]. 
Table-3: EPA and DHA effect on thrombogenesis related factors [46] 
  EPA  DHA 
Thrombosis and 
coagulation 
↓ Collagen-stimulated platelet aggregation ↓ Collagen-stimulated platelet aggregation 
Otherwise minimal effects on thrombosis or 
coagulation 
Otherwise minimal effects on thrombosis or 
coagulation 
Endothelial function  
Reduces inflammation  Reduces inflammation 
Reduces oxidative stress  Reduces oxidative stress  
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decrease in low-density lipoprotein and an increase in 
high-density lipoprotein which is associated with 
reduced incidences of coronary heart diseases. 
 
    Although there is less recent randomized clinical 
trials evidence examining the effects of dietary fats on 
various outcomes, a large body examining the impact 
of dietary fat on lipid profiles has been reported. A 
higher level of atherogenic cholesterol or cholesterol 
carried in non-HDL vesicles, and LDL has been 
implicated in atherosclerosis [65]. Corn olive oil       
has been shown to reduce LDL and the total cholesterol  
 
level [66]. However, the study by [8] reported no 
significant effects while comparing the effects on blood  
lipid after consumption PUFAs, although the study was 
dominated by findings of one paper. A systematic 
review by [67] also reported that the use of canola oil 
reduces low-density lipoprotein but had no effect on 
high-density lipoproteins. Guidelines in managing the 
condition are associated with reducing the 
concentrations of LDL cholesterol. The replacement of 
saturated fatty acids (SFA) with PUFAs lowers 
cholesterol LDL and changes the triglycerides: HDL 
cholesterol level as shown in (Table-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
       
Fig-9: 
    Effect of EPA: DHA ratios of 6:1 and 1:1 on veins. Acetylcholine levels reduce, resulting in the relaxation of veins [59]. 
Table-4: Changes in total cholesterol (Total-C), LDL Cholesterol, HDL cholesterol, Total-C/HDL 
cholesterol and TGs when diets are changed from SFA to carbohydrates( CHO), SFAs to 
Monounsaturated fatty acid ( MUFA) and SFA to PUFAs [68] 
Change (mmol/L) per 1% energy replaced 
Lipoprotein lipid SFAs → CHO SFAs → MUFAs SFAs → PUFAs 
Total-C  −0.041 (−0.047, −0.035) −0.046 (−0.051, −0.040) −0.064 (−0.070, −0.058) 
LDL cholesterol  −0.033 (−0.039, −0.027) −0.042 (−0.047, −0.037) −0.055 (−0.061, −0.050) 
HDL cholesterol  −0.010 (−0.012, −0.008) −0.002 (−0.004, 0.000) −0.005 (−0.006, −0.003) 
Total-C/HDL cholesterol  0.001 (−0.006, 0.007) −0.027 (−0.033, −0.022) −0.034 (−0.040, −0.028) 
TGs  0.011 (0.007, 0.014) −0.004 (−0.007, −0.001) −0.010 (−0.014, −0.007) 
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    ApoA-I is regarded as the main protein component 
present in HDL particles, which promotes the 
maturation of HDL by allowing cholesterol efflux from 
various cells [69]. It also stimulates cholesterol 
esterification through the activity of the enzyme 
lecithin cholesterol acyltransferase (LCAT) [70]. 
Plasma levels of LCAT increase with the consumption 
of highly enriched omega-3 oil [17]. Consumption of 
omega-3 increases the hepatic and plasma expression 
of ApoA-I and is linked with the anti-oxidative activity 
of HDLs. ApoA-I stabilises the activity of paraoxonase-1 
(PON1) which is linked to HDL [71]. PON1 reduces the 
oxidative stress associated with macrophages, reduces 
the production of proinflammatory cytokines [72], and 
increases cholesterol efflux capacity of macrophages 
[73], as shown in (Fig-10). 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     The study by [75] reported that lipoprotein 
apheresis could be used in managing atherosclerosis. 
Lipoprotein apheresis decreases levels of essential 
omega 3 and omega 3 PUFAs in blood plasma, but the 
use of heparin-induced extracorporeal low-density 
lipoprotein precipitation (HELP) is associated with 
proinflammatory activity of omega-3 and -6 PUFAs. 
HELP-treated patients showed cardioprotective effects 
and limited inflammatory reaction HDL levels 
increasing and a reduction being observed in HDL and 
no significant differences being observed in LDL, 
cholesterol, and triglycerides, as shown in (Fig-11). 
The result recommending omega-3 supplementation in 
lipid apheresis could have additional benefits. 
 
    The blow (Table-5) summaries the effect of PUFAs 
on cardiometabolic health. 
 
    Further analysis reveals that the use of EPA and 
DHA is linked to a reduction in cardiovascular 
outcomes, as indicated by the relative risks across 
various studies indicated below (Table-6). Individuals 
who did not take EPA and DHA had higher relative 
risks of developing coronary heart diseases as 
compared to those using PUFA [76]. High levels of 
triglycerides and lipoproteins were also observed 
among those who did not take PUFA. 
 
 
 
     
Fig-10: 
   The effects of omega-3 PUFAs on cholesterol efflux and paraoxonase 1 [74]. 
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Fig-11: 
    HELP-treated patients showing differences in lipid profiles [75]. 
Table-5: The action of PUFA on cardiometabolic health summary [72] 
  Omega 3 Omega 6 
Cholesterol 
EPA and DHA reduces levels of Low-density 
lipoproteins (LDL) and increases levels of High-
Density Lipoproteins (HDL) 
Less scientific data on the effect of omega 6 on 
HDL and LDL levels 
Thrombogenesis  
Formation of protecin DX which limits the 
activity of cyclooxygenase 1 and 2  
Inhibiting the synthesis of thromboxane A2, which 
affects the production of arachidonic acid, 
decreasing the activity of cyclooxygenase 1. 
Inflammation 
Activation and binding of Beta-arrestin-2, which 
breaks down to produce TABI, which inhibits 
TAKI and disrupting the remaining pathways. 
The presence of DHA and EPA interferes with the 
translocation of TLR-4, which serves to inhibit 
the production of cytokines. 
Dietary linoleic acid increase s activity of 
cyclooxygenase 2 which increases the conversion 
of arachidonic acid to proinflammatory eicosanoid 
in the process reducing the concentration of 
arachidonic acid 
Blood pressure 
and hypertension  
Conversion of prostaglandins to arachidonic acid 
and subsequent release of vasodilators like nitric 
oxide. 
Inhibition of ACE and the role of cytochrome p450 
in activating nitric oxide 
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Table-6: A meta-analysis table – table constructed to highlight the main contents of this literature review 
based on thorough analysis of all the primary research, studies and data involved  
Author Title Relevance to the topic 
[7] 
Omega-3, omega-6, and total dietary 
polyunsaturated fat for prevention and 
treatment of type 2 diabetes mellitus: 
Systematic review and meta-analysis of 
randomized controlled trials. 
[7] established elevated LDL-cholesterol as atherosclerosis and 
CVD risk factor. The research that they conducted 
demonstrated that increased ω-3 and ω-6 intake had 
hypocholesterolaemia effects. However, the information 
provided in their study concerning the specific effects of ω-6 
PUFA on blood lipid profiles is limited.  
[1] 
Polyunsaturated fatty acids for the primary 
and secondary prevention of cardiovascular 
disease 
Most of the RCT data used by [1] in his study to determine the 
effects of PUFAs on cardiometabolic diseases was quite old. 
From his findings, replacement of 5% SFAs by PUFAs 
significantly reduced CAD risks.  
[6] 
Overweight, obesity, and risk of 
cardiometabolic multimorbidity 
[6] in their work, conducted a Cochrane meta-analysis where 
they examined SFA intake reduction and replacing it with 
PUFA or MUFA. Their research concluded that replacement of 
SFAs with ω-3 and ω-6 PUFAs resulted in a 17% reduction in 
cardiometabolic events. They reported that, replacing some 
saturated fats with PUFAs having plants origin resulted 
yielded lower cardiometabolic disease risk. Subgroup analysis 
conducted showed lower risks in PUFA compared to SFA 
groups. 
[11] 
Biochemical mechanism of the ratio of omega 
6 to 3 fatty acids on blood lipid reduction 
[11] literature is relevant to this study, where they conducted a 
crossectional analysis of Spanish men considered obese. The 
men underwent laparoscopic gastric bypass surgery. Analysis 
of the abdominal adipose tissue and venous blood serum was 
conducted to calculate FA composition. A positive correlation 
of ω-6 PUFAs with HDL-C and an inverse correlation with 
triglycerides  (TG) was found. 
[13] 
The ratio of dietary ω-3 and ω-6 fatty acids 
independent determinants of muscle mass in 
hemodialysis patients with diabetes. 
[13] conducted observational studies among the East Asian 
and Asian Indian population, which is relevant to this study. 
They found out through research that, omega 6 PUFAs to be 
inversely associated with TG across the population studied. A 
cross-sectional analysis conducted on male cohort found 
serum LA to be positively associated with HDL-C particle size 
and inversely associated with LDL-C and VLDL particle sizes. 
[15] 
A systematic review of the effect of dietary 
saturated and polyunsaturated fat on heart 
disease 
[15] carried out a meta-analysis of 80 controlled 
interventional trials where they concluded that n-6 PUFA has 
beneficial effects on blood lipid levels. The total PUFAs can be 
considered to be equal to omega 6 PUFA with a number of 18 
carbons.  
[22] 
Inflammatory markers and extent and 
progression of early atherosclerosis: Meta-
analysis of individual-participant-data from 20 
prospective studies of the PROG-IMT 
collaboration. 
Their research associated a reduction in blood pressure with a 
reduction in CVD risks. They concluded in their research that 
dietary LA is inversely associated with blood pressure (BP)  
[29] 
The associations of serum n-6 
polyunsaturated fatty acids with serum C-
reactive protein in men: The Kuopio Ischaemic 
Heart Disease Risk Factor Study 
Cardiometabolic conditions are directly attributed to 
modifiable behaviors such as sedentary activity and poor diet. 
Omega 3 (C20–22 ω 3) polyunsaturated fatty acids have 
pleiotropic effects on the functioning of cells, control 
inflammatory factors and cellular events in vascular 
endothelial cells and cardiomyocytes. The hypolipemic, anti-
arrhythmic, and anti-inflammatory properties of fatty acids 
offer cardioprotection. 
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Conclusion 
    Cardiometabolic diseases are significant health and 
economic burden globally since they contribute to 
preventable mortality and morbidity in individuals of 
all ages, races, and genders. One of the most effective 
approaches towards the prevention and management 
of cardiometabolic diseases include lifestyle and 
dietary changes. Based on the meta-analysis, ω-3 and 
ω-6 PUFAs are essential fatty acids in the body 
functioning, and since they are not synthesized in the 
human body, they are mostly consumed through the 
dietary sources and nutritional supplements. The 
significance of ω -3 PUFAs on cardiometabolic is clear 
that is the reduction of inflammation agents that may 
contribute to metabolic syndrome as well as being 
essential in the prevention of cardiovascular diseases 
like thrombosis. Similarly, ω-6 PUFAs are important in 
the promotion of cardiovascular health by lowering 
cholesterol levels. Despite the highlighted benefits of 
the two fatty acids on cardiometabolic health, a 
significant controversy relates to the question as to 
whether ω-6 PUFAs contribute to inflammation or not. 
For instance, the conversion of SFA to PUFAs is always 
associated with a brisk of increasing inflammation. 
Omega 3- and 6 fatty acids have also been indicated to 
compete for substrates, and as a result, omega-3 is 
linked with anti-inflammatory behavior while omega-6 
is linked with proinflammatory behavior. Also, the 
formation of omega-6 fatty acids is associated with the 
release of inflammatory molecules such as 
leukotrienes. The effect of downstream products 
produced by omega-3 and omega-6 fatty acids in 
relation to inflammation also remains unknown, while 
other studies suggest that inflammation linked to 
omega-6 could be explained by the highomega-3 to 
omega 6 ratios. Thus, there is a need to carry out more 
research on the link between omega-6 PUFAs and 
inflammation with specific emphasis being placed on 
the exact mechanism. 
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